WO2019227253A1 - miRNA-21过表达载体的构建及其应用 - Google Patents

miRNA-21过表达载体的构建及其应用 Download PDF

Info

Publication number
WO2019227253A1
WO2019227253A1 PCT/CN2018/088528 CN2018088528W WO2019227253A1 WO 2019227253 A1 WO2019227253 A1 WO 2019227253A1 CN 2018088528 W CN2018088528 W CN 2018088528W WO 2019227253 A1 WO2019227253 A1 WO 2019227253A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
expression vector
mirna
construction
application
Prior art date
Application number
PCT/CN2018/088528
Other languages
English (en)
French (fr)
Inventor
毛吉炎
Original Assignee
深圳市博奥康生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市博奥康生物科技有限公司 filed Critical 深圳市博奥康生物科技有限公司
Priority to PCT/CN2018/088528 priority Critical patent/WO2019227253A1/zh
Publication of WO2019227253A1 publication Critical patent/WO2019227253A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Definitions

  • the invention belongs to the field of genetic engineering, and particularly relates to the construction and application of a miRNA-21 overexpression vector.
  • MicroRNA is a type of small single-stranded short RNA with a length of about 22 to 25 nucleotides. Although it does not encode a protein, it can bind to homologous mRNA in an incomplete base-pairing manner and inhibit it. The expression of mRNA may induce its degradation, thereby negatively regulating mRNA and affecting the production of related proteins.
  • miRNAs are regulated by miRNAs, and they are almost involved in a series of physiological and biochemical processes such as cell growth, differentiation, apoptosis, glucose metabolism, fat metabolism, insulin secretion, brain formation, cardiac development, and stem cell differentiation. The occurrence of diseases, including tumors, is closely related.
  • miRNA-21 is closely related to cell proliferation and anti-apoptotic ability. It is used in a variety of solid tumors (breast cancer, gastric cancer, lung cancer, liver cancer, prostate cancer, pancreatic cancer, colon cancer, esophageal cancer, etc.) and non-solid tumors (chronic lymphoma). Cellular leukemia, B-cell lymphoma, etc.) have been found to be activated, but its carcinogenic mechanism is unclear, and there are fewer reports on related studies.
  • the present invention studies the role of miR-21 in tumors by constructing a miR-21 overexpression recombinant vector and overexpressing it in HepG2 cells.
  • the experimental results showed that the recombinant vector was successfully and efficiently expressed at the cellular level, and the expression level of miR-21 was significantly increased.
  • the object of the present invention is to provide a miR-21 overexpression recombinant expression vector, which contains the sequence shown in SEQ ID No.1.
  • the vector is pcDNA3.1.
  • Another object of the present invention is to provide a method for constructing the miR-21 overexpression recombinant expression vector, which method comprises: a. Designing primers and PCR-amplifying the miR-21 gene; b. The amplified gene and expression vector enzyme Cut, ligate the gene of interest and the expression vector; c. Transform the ligated product into E. coli and culture; d. Extract the recombinant plasmid after identification.
  • upstream primer 5'-CATCAGTCTGATAAGCTACCCGACA-3 '
  • downstream primer 5'-TGTCAGACAGCCCATCGACTGGTG-3'.
  • the miR-21 overexpression recombinant vector provided by the present invention can greatly increase the expression level of miR-21 in tumor cells, and provides a new technical means for studying the role of miR-21 in tumorigenesis and development.
  • Figure 1 is the PCR result of the target gene
  • Figure 2 shows miR-21 expression levels in control and experimental HepG2 cells.
  • a 100 ⁇ g / ml ampicillin-containing LB medium was used to incubate the correctly sequenced E. coli at 37 ° C.
  • the pcDNA-miR21 recombinant plasmid was extracted without endotoxin.
  • HepG2 cells were seeded into a six-well plate at a seeding density of 50%.
  • Transduction Take 1 ⁇ g pcDNA-miR21 recombinant plasmid and 3 ⁇ l PEI (1 ⁇ g / ⁇ l) in 100 ⁇ l Opti-MEM medium, and vortex to mix. The medium in the six-well plate was changed to serum-free medium, 1.4 ml per well, and 600 ⁇ l of the transfection mixture was added, and replaced with DMEM medium preheated with 10% fetal bovine serum at 37 ° C. for 5 h. Incubate at 37 ° C for 5% CO2, 90% humidity for 48 h, and collect cells.
  • Example 2 The total RNA of the cells collected in Example 2 was quantified by the probe method Hairpin-it miRNAs quantification and U6 calibration qRT-PCR kit (GenePharma) for fluorescent quantitative PCR. For specific methods, refer to the kit instructions. The results are shown in Figure 2.
  • HepG2 cells (experimental group) transduced with pcDNA-miR21 recombinant plasmid were detected by fluorescent quantitative PCR.
  • the miR-21 expression level was 172.8 times higher than that of normal HepG2 cells (control group), indicating that the pcDNA-miR21 recombinant plasmid Can efficiently express miR-21.
  • the miR-21 overexpression recombinant vector provided by the present invention can greatly increase the expression level of miR-21 in tumor cells, and provides a new technical means for studying the role of miR-21 in tumorigenesis and development.

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

提供了一种miR-21过表达重组载体及其构建方法和应用。通过构建miR-21过表达重组载体并在HepG2细胞中过表达，研究miR-21在肿瘤中的作用。

Description

miRNA-21过表达载体的构建及其应用 技术领域
本发明属于基因工程领域，尤其涉及一种miRNA-21过表达载体的构建及其应用。
 背景技术
MicroRNA（miRNA）是一类长度约为22～25个核苷酸的单链短序列小RNA，尽管其不编码蛋白质，但却能以非完全性碱基配对的方式结合于同源mRNA，抑制mRNA的表达或是诱导其降解，从而对mRNA进行负性调控，影响相关蛋白的生成。人类有三分之一的基因受miRNA调控，几乎参与了细胞生长、分化、凋亡、糖代谢、脂肪代谢、胰岛素分泌、大脑形成、心脏发生、干细胞分化等一系列生理生化进程，并与许多疾病（包括肿瘤）的发生密切相关。
 技术问题
miRNA-21与细胞的增殖和抗凋亡能力密切相关，在多种实体肿瘤（乳腺癌、胃癌、肺癌、肝癌、前列腺癌、胰腺癌、结肠癌、食管癌等)及非实体瘤(慢性淋巴细胞性白血病、B细胞性淋巴瘤等)中均被发现激活，但其致癌机制尚不清楚，相关研究的报道也较少。
 技术解决方案
本发明通过构建miR-21过表达重组载体并在HepG2细胞中过表达，研究miR-21在肿瘤中的作用。实验结果显示，该重组载体在细胞水平成功高效表达，miR-21表达水平大幅提升。
本发明的目的是提供miR-21过表达重组表达载体，其含有如SEQ ID No.1所示的序列。
所述载体为pcDNA3.1。
本发明的另一个目的是提供构建所述miR-21过表达重组表达载体的方法，该方法包括：a. 设计引物，PCR扩增miR-21基因；b. 将扩增的基因和表达载体酶切，连接目的基因和表达载体；c. 将连接产物转化大肠杆菌，培养；d. 鉴定后提取重组质粒。
所述引物序列：上游引物：5’-CATCAGTCTGATAAGCTACCCGACA-3’；下游引物：5’-TGTCAGACAGCCCATCGACTGGTG-3’。
 有益效果
本发明提供的miR-21过表达重组载体可大幅提升miR-21在肿瘤细胞中的表达水平，为研究miR-21在肿瘤发生发展中的作用提供了新的技术手段。
 附图说明
图1 为目的基因PCR结果；
图2 为对照组和实验组HepG2细胞的miR-21表达水平。
 本发明的实施方式
下面结合附图与具体实施例对本发明做进一步的说明。
实施例一 miR-21 过表达载体构建
1、序列获得和引物设计
从Genbank中找到人miR-21基因序列（登录号：AC004686.2），利用Primer 5软件分别选取各个CDS两端的部分序列进行分析，确定上下游引物序列，并委托上海英潍捷基公司合成引物。所述引物序列：上游引物：5’-CATCAGTCTGATAAGCTACCCGACA-3’；下游引物：5’-TGTCAGACAGCCCATCGACTGGTG-3’。
2、目的基因序列的获得
将新合成的引物加入TE buffer溶解，调整引物的最终浓度为10μM，以HepG2细胞基因组DNA为模板，加入引物，Premix PrimeSTAR HS进行扩增，扩增条件如下：98℃ 5 min，1个循环；98℃ 5 s，56℃ 5 s，72℃ 10 s，30个循环。PCR产物通过1%琼脂糖凝胶电泳进行鉴定，如图1所示。然后切胶回收纯化PCR产物。
Bam HI和Xho I分别双酶切pcDNA3.1质粒和PCR产物，回收后按pcDNA3.1质粒：PCR产物为1:5混合后，T4 DNA连接酶16℃连接过夜。转化大肠杆菌Top 10，氨苄青霉素筛选培养并挑单克隆菌株，测序鉴定，获得pcDNA-miR21质粒。
实施例二 HepG2 细胞转导
用含100 μg/ml氨苄青霉素的LB培养基，37℃大量培养测序正确的大肠杆菌，无内毒素提取pcDNA-miR21重组质粒。
转染前一天将HepG2细胞接种至六孔板，接种密度50%。转导：取1 μg pcDNA-miR21重组质粒和3 μl PEI（1 μg/μl）溶于100 μl Opti-MEM培养基，涡旋混匀。将六孔板内培养基换成无血清培养基，每孔1.4 ml，并加入600 μl转染混合液，5 h换成37℃预热有10% 胎牛血清的DMEM培养基。置37℃ 5% CO2，90% 湿度培养48 h，收集细胞。
实施例三   miR-21 表达水平的鉴定
提取实施例二中收集细胞的总RNA，探针法Hairpin-it miRNAs定量和U6校准qRT-PCR试剂盒(GenePharma)进行荧光定量PCR，具体方法参照试剂盒说明书，结果见图2。
如图2所示，荧光定量PCR检测转导了pcDNA-miR21重组质粒的HepG2细胞（实验组），其miR-21表达水平较正常HepG2细胞（对照组）高172.8倍，说明pcDNA-miR21重组质粒可高效表达miR-21。
 工业实用性
本发明提供的miR-21过表达重组载体可大幅提升miR-21在肿瘤细胞中的表达水平，为研究miR-21在肿瘤发生发展中的作用提供了新的技术手段。

Claims (3)

  1. 一种miR-21过表达重组表达载体，其含有如SEQ ID No.1所示的序列。
  2. 构建权利要求1所述的miR-21过表达重组表达载体的方法，该方法包括：a. 设计引物，PCR扩增miR-21基因；b. 将扩增的基因和表达载体酶切，连接目的基因和表达载体；c. 将连接产物转化大肠杆菌，培养；d. 鉴定后提取重组质粒。
  3. 根据权利要求2所述的方法，其中所述引物为：
    上游引物：5’-CATCAGTCTGATAAGCTACCCGACA-3’
    下游引物：5’-TGTCAGACAGCCCATCGACTGGTG-3’
PCT/CN2018/088528 2018-05-26 2018-05-26 miRNA-21过表达载体的构建及其应用 WO2019227253A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/088528 WO2019227253A1 (zh) 2018-05-26 2018-05-26 miRNA-21过表达载体的构建及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/088528 WO2019227253A1 (zh) 2018-05-26 2018-05-26 miRNA-21过表达载体的构建及其应用

Publications (1)

Publication Number Publication Date
WO2019227253A1 true WO2019227253A1 (zh) 2019-12-05

Family

ID=68696737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/088528 WO2019227253A1 (zh) 2018-05-26 2018-05-26 miRNA-21过表达载体的构建及其应用

Country Status (1)

Country Link
WO (1) WO2019227253A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159633A1 (en) * 2013-03-14 2014-10-02 Medimmune, Llc Recombinant polypeptide production
CN105878264A (zh) * 2016-06-13 2016-08-24 山东大学 miR-21及其抑制剂在制备促进牙周组织再生药物中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159633A1 (en) * 2013-03-14 2014-10-02 Medimmune, Llc Recombinant polypeptide production
CN105878264A (zh) * 2016-06-13 2016-08-24 山东大学 miR-21及其抑制剂在制备促进牙周组织再生药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIANG, BIN: "Practical Study on Technology of Construction of MicroRNA Overexpression Vector", EXPERIMENTAL TECHNOLOGY AND MANAGEMENT, vol. 31, no. 1, 20 January 2014 (2014-01-20), pages 41 - 44, ISSN: 1002-4956 *
JIANG, JINGHANG ET AL.: "Overexpression of Microrna-21 Strengthens Stem Cell -Like Characteristics in a Hepatocellular Carcinoma Cell Line", WORLD JOURNAL OF SURGICAL ONCOLOGY, vol. 14, 28 October 2016 (2016-10-28), pages 1 - 9, XP055657696, ISSN: 1477-7819 *

Similar Documents

Publication Publication Date Title
Strotbek et al. Stable microRNA expression enhances therapeutic antibody productivity of Chinese hamster ovary cells
EP2937417B1 (en) MiRNAs enhancing cell productivity
Luo et al. microRNA133a targets Foxl2 and promotes differentiation of C2C12 into myogenic progenitor cells
US10006026B2 (en) Recombinant polypeptide production
CN109837301B (zh) 人源化幽门螺旋杆菌cagA真核表达载体构建方法
CN112899238B (zh) 基于RNA-m6A修饰水平的化合物筛选细胞模型及其构建与应用
Kellner et al. Targeting miRNAs with CRISPR/Cas9 to improve recombinant protein production of CHO cells
EP1728859A1 (en) Sequence capable of accelerating gene expression at moderately low temperature
CN114517198B (zh) 一种半滑舌鳎miRNA及其在调控tgfb2基因表达中的应用
WO2019227253A1 (zh) miRNA-21过表达载体的构建及其应用
Wang et al. RIP-Seq of EZH2 Identifies TCONS-00036665 as a Regulator of Myogenesis in Pigs
CN110564743B (zh) 一种六盘山黄牛circR-UQCC1基因及其过表达载体、构建方法和应用
TWI646194B (zh) 用於產生供製造重組蛋白之哺乳動物製造細胞之手段和方法
WO2019227254A1 (zh) miRNA-25过表达载体的构建及其应用
WO2019227256A1 (zh) miRNA-145过表达载体的构建及其应用
WO2019227257A1 (zh) miRNA-210过表达载体的构建及其应用
WO2019227255A1 (zh) miRNA-128过表达载体的构建及其应用
CN116904469B (zh) 一种p300蛋白表达的抑制剂和制备方法及其用途
CN114107495B (zh) Duxap8在子宫内膜癌诊断、治疗和预防中的应用
CN110527682B (zh) 一种长链非编码rna及其应用
Takizawa et al. Basic and clinical studies on functional RNA molecules for advanced medical technologies
KR20120116766A (ko) Ａｄｅｎｉｎｅ ｎｕｃｌｅｏｔｉｄｅ ｔｒａｎｓｌｏｃａｔｏｒ ２ 발현 또는 활성 억제제를 이용한 간암 치료 방법
Li et al. Circular RNA (circRNA) and YAP in tumor: A review
CN115417919A (zh) 一种ascc3多肽构建及其抗肝癌活性应用
CN116515903A (zh) 一种dna核酸适体的制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18920912

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18920912

Country of ref document: EP

Kind code of ref document: A1